Condition: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency · Autosomal Recessive Hypophosphatemic Rickets · Generalized Arterial Calcification of Infancy · Sponsor: Inozyme Pharma
The primary purpose of Study INZ701-104 (the ENERGY study) is to assess the safety and tolerability of INZ-701 in infants with ENPP1 Deficiency or with ABCC6 Deficiency.
This description comes directly from the study's public registry record.
Trial Specialist · +1 800-983-4587 · medinfo@bmrn.com
Medical Director, MD · +1 800-983-4587 · medinfo@bmrn.com
Always discuss trial participation with your own doctor first.
| Rady Children's Hospital | San Diego, California, United States | Recruiting |
| Boston Children's Hospital | Boston, Massachusetts, United States | Withdrawn |
| Nationwide Children's Hospital | Columbus, Ohio, United States | Recruiting |
| The Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| The University of Utah | Salt Lake City, Utah, United States | Withdrawn |
| Hospital Sant Joan de Déu | Barcelona, Spain | Terminated |
| Royal Manchester Children's Hospital | Manchester, United Kingdom | Terminated |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05734196